Survodutide shows notable weight reduction in people with type 2 diabetes and obesity
A once-weekly GLP-1/glucagon dual agonist produced body weight reductions of as much as 9.8% at 76 weeks in adults with type 2 diabetes and overweight or obesity, according to…
4 min read · Updated 2026-10-01